Korro Bio (KRRO) Interest Expenses (2018 - 2026)
Korro Bio's (KRRO) quarterly Interest Expenses came in at $22.7 million in Q1 2026, up 11257.5% YoY from N/an in Q1 2025, and up 22615.0% on a QoQ basis from $100000.0 in Q4 2025.
Korro Bio (KRRO) Interest Expenses (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Interest Expenses data on file, last reported at $22.7 million in Q1 2026.
- Quarterly Interest Expenses rose 11257.5% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.7 million (up 3685.83% YoY) and the FY2025 annual result came in at $202.3 million, up 849.19% from the prior year.
- Interest Expenses climbed to $22.7 million in Q1 2026, from $100000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $71.9 million in Q3 2024 to a low of -$449000.0 in Q4 2022.
- A 5-year average of $14.5 million and a median of $284000.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 346.7% — and 2024, when it jumped 2395466.67%.
- Tracing KRRO's Interest Expenses over 5 years: stood at -$449000.0 in 2022, then soared by 122.27% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then jumped by 22615.0% to $22.7 million in 2026.
- The last three Interest Expenses figures came in at $22.7 million (Q1 2026), $100000.0 (Q4 2025), and $42.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.75 Mn |
| Jun 30, 2026 | 63.75 Mn |
| Mar 31, 2026 | 22.72 Mn |
| Mar 31, 2026 | 22.72 Mn |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 42.06 Mn |
| Sep 30, 2025 | 42.06 Mn |
| Jun 30, 2025 | 36.71 Mn |
| Jun 30, 2025 | 36.71 Mn |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 71.87 Mn |
| Sep 30, 2024 | 71.87 Mn |
| Jun 30, 2024 | 69.68 Mn |
| Jun 30, 2024 | 69.68 Mn |
| Mar 31, 2024 | 200,000.00 |
| Mar 31, 2024 | 200,000.00 |